Krzysztof Mądry

Medical University of Warsaw — Poland

Medicine · Health Sciences

19h-index1.4kcitations124works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(65), Chronic Lymphocytic Leukemia Research(20), Acute Lymphoblastic Leukemia research(18), Multiple Myeloma Research and Treatments(17), Myeloproliferative Neoplasms: Diagnosis and Treatment(17)

Publications123 total

Miejsce luspaterceptu w leczeniu pacjentów z nowotworami mielodysplastycznymi niskiego ryzyka w 2025 roku
Hematologia — Edukacja·2025Open Access
Luspatercept initiated at the maximum-approved dose in transfusion-dependent lower-risk myelodysplastic syndromes: Interim analysis from maxilus
Blood·2025
A multi-center study of a machine learning algorithm for identifying undiagnosed patients with myelodysplastic syndrome based on complete blood count data
Blood·2025Open Access
AI-powered precision: Unmasking hidden treatment optimizations for lower-risk myelodysplastic syndrome patients based on real-world, multi center EHR data.
Blood·2025
Diagnostic and therapeutic advances in MDS
Acta Haematologica Polonica·2025Open Access
MDS-736: Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Clinical Lymphoma Myeloma & Leukemia·2025
POSTER: MDS-736 Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Clinical Lymphoma Myeloma & Leukemia·2025
Venetoclax/azacitidine for the treatment of acute myeloid leukemia: real-life experience prospective single center study
Hematology in Clinical Practice·2025Open Access
River-52: A Multicenter, Open-Label Clinical Trial of RVU120 in Patients with Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
Blood·2024· 1 citedOpen Access
The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)
Blood·2024Open Access
River-81: A Multicenter, Open-Label, Dose-Finding Clinical Trial to Assess Safety, PK, PD, Clinical Efficacy of RVU120 in Combination with Venetoclax in Patients with AML Failing Prior Venetoclax Plus Hypomethylating Agent Therapy
Blood·2024· 1 cited
The Premature Reduction of Venetoclax in an Initial Cycle of Ven-AZA Regimen for Unfit AML Patients Leads to Shortened Overall Survival - a Retrospective Study of Polish Adult Leukemia Group (PALG)
Blood·2024· 1 cited
Stem Cell Mobilization Performed with Different Doses of Cytarabine in Plasma Cell Myeloma Patients Relapsing after Previous Autologous Hematopoietic Cell Transplantation—A Multicenter Report by the Polish Myeloma Study Group
Cancers·2024Open Access
Roxadustat versus placebo for patients with lower‐risk myelodysplastic syndrome: MATTERHORN phase 3, double‐blind, randomized controlled trial
American Journal of Hematology·2024· 13 citedOpen Access
No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine—a prospective multicenter study by the Polish Adult Leukemia Group
Frontiers in Oncology·2024· 2 citedOpen Access
Characteristics and outcomes of patients with lymphoma who developed therapy-related acute myeloid leukemia or myelodysplastic syndrome – a retrospective analysis of the Polish Adult Leukemia Group
Współczesna Onkologia·2024· 1 citedOpen Access
Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive Chemotherapy
Cancers·2023· 2 citedOpen Access
Efficacy and Safety of Roxadustat for Treatment of Anemia in Patients with Lower-Risk Myelodysplastic Syndrome (LR-MDS) with Low Red Blood Cell (RBC) Transfusion Burden: Results of Phase III Matterhorn Study
Blood·2023· 5 citedOpen Access
Higher Prevalence of Chronic Kidney Disease in Myelodysplastic Syndromes Patients Compared to Age- Adjusted General Population - Results from the Polish Adult Leukemia Group (PALG) Registry
Blood·2023Open Access
POSTER: AML-384 Real-World Efficacy and Hematologic Toxicity of Azacitidine and Venetoclax in a Cohort of Elderly Patients Unfit for Intensive Chemotherapy With Newly Diagnosed Acute Myeloid Leukemia
Clinical Lymphoma Myeloma & Leukemia·2023
page 1 of 7Next →

Frequent Co-authors

Joanna Drozd‐Sokołowska(18), Jadwiga Dwilewicz‐Trojaczek(17), W Wiktor-Jędrzejczak(16), Grzegorz Basak(16), Anna Waszczuk‐Gajda(16), Reinhard Stauder(14), Pierre Fenaux(14), Luca Malcovati(14), David Bowen(14), Argiris Symeonidis(13), Guillermo Sanz(13), Jaroslav Čermák(13), Moshe Mittelman(13), Eva Hellström‐Lindberg(13), Théo de Witte(13), Mette Skov Holm(12), Saskia Langemeijer(11), Ulrich Germing(10), Corine van Marrewijk(10), Agnès Guerci‐Bresler(10)